KYTX Kyverna Therapeutics Inc.

Price (delayed)

$7.96

Market cap

$483.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.27

Enterprise value

$484.94M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5

We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to bring disease-modifying therapeutic benefits to patients suffering from ...

Highlights
Kyverna Therapeutics's EPS has increased by 10% from the previous quarter and by 3.3% YoY
Kyverna Therapeutics's quick ratio has increased by 9% YoY and by 4.2% from the previous quarter
The net income has declined by 8% year-on-year but it is up by 3% since the previous quarter
Kyverna Therapeutics's debt has increased by 16% QoQ
KYTX's equity is down by 16% since the previous quarter and by 13% year-on-year

Key stats

What are the main financial stats of KYTX

KYTX stock price

How has the Kyverna Therapeutics stock price performed over time
Intraday
1.79%
1 week
-7.98%
1 month
-11.56%
1 year
179.3%
YTD
-15.32%
QTD
-7.76%

Financial performance

How have Kyverna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$163.79M
Net income
-$156.4M
Gross margin
N/A
Net margin
N/A
The net income has declined by 8% year-on-year but it is up by 3% since the previous quarter
KYTX's operating income is up by 3.6% QoQ

Price vs fundamentals

How does KYTX's price correlate with its fundamentals

Growth

What is Kyverna Therapeutics's growth rate over time

Valuation

What is Kyverna Therapeutics stock price valuation
P/E
N/A
P/B
2.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kyverna Therapeutics's EPS has increased by 10% from the previous quarter and by 3.3% YoY
The price to book (P/B) is 42% higher than the last 4 quarters average of 1.7
KYTX's equity is down by 16% since the previous quarter and by 13% year-on-year

Efficiency

How efficient is Kyverna Therapeutics business performance
The company's return on equity has shrunk by 59% YoY
The company's return on assets fell by 41% YoY but it rose by 2.6% QoQ
KYTX's ROIC is down by 29% YoY but it is up by 11% QoQ

Dividends

What is KYTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYTX.

Financial health

How did Kyverna Therapeutics financials performed over time
KYTX's total liabilities has soared by 68% YoY
Kyverna Therapeutics's total assets has decreased by 13% from the previous quarter
Kyverna Therapeutics's debt is 83% lower than its equity
KYTX's debt to equity is up by 42% QoQ
Kyverna Therapeutics's debt has increased by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.